[go: up one dir, main page]

PE20050081A1 - Nuevas imidazopirazinas como inhibidores de cinasas dependientes de ciclinas - Google Patents

Nuevas imidazopirazinas como inhibidores de cinasas dependientes de ciclinas

Info

Publication number
PE20050081A1
PE20050081A1 PE2003000961A PE2003000961A PE20050081A1 PE 20050081 A1 PE20050081 A1 PE 20050081A1 PE 2003000961 A PE2003000961 A PE 2003000961A PE 2003000961 A PE2003000961 A PE 2003000961A PE 20050081 A1 PE20050081 A1 PE 20050081A1
Authority
PE
Peru
Prior art keywords
cycline
inhibitors
dependent kinases
imidazopyrazines
new
Prior art date
Application number
PE2003000961A
Other languages
English (en)
Inventor
Ronald J Doll
Alan K Mallams
Vyyoor Moopil Girijavallabhan
Michael P Dwyer
Timothy J Guzi
Kamil Paruch
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20050081A1 publication Critical patent/PE20050081A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA III, DONDE R ES H, HALOGENO, ARILO, ENTRE OTROS; R1 ES H, HALOGENO, ALQUILO; R2 ES HALOGENO, ARILALQUILO, HETEROCICLILO, ENTRE OTROS. TAMBIEN REFERIDA A LA PREPARACION DE UNE COMPOSICION FARMACEUTICA QUE LO COMPRENDE SIENDO COMPUESTOS PREFERIDOS (A) Y (B), ENTRE OTROS; Y QUE ADICIONALMENTE COMPRENDE UNO O MAS ANTICANCERIGENOS SELECCIONADOS DE TAXOTERO, ETOPOSIDA, IRINOTECAN, PACLITAXEL, ADRIAMICINA, ENTRE OTROS. DICHOS COMPUESTOS SON INHIBIDORES DE CINASAS DEPENDIENTES DE CICLINA, UTILES EN LA MEJORIA DE ENFERMEDADES ASOCIADAS CON LAS CDK COMO EN DIVERSOS TIPOS DE CANCER
PE2003000961A 2002-09-23 2003-09-19 Nuevas imidazopirazinas como inhibidores de cinasas dependientes de ciclinas PE20050081A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41299702P 2002-09-23 2002-09-23

Publications (1)

Publication Number Publication Date
PE20050081A1 true PE20050081A1 (es) 2005-03-01

Family

ID=32030951

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000961A PE20050081A1 (es) 2002-09-23 2003-09-19 Nuevas imidazopirazinas como inhibidores de cinasas dependientes de ciclinas

Country Status (18)

Country Link
US (2) US6919341B2 (es)
EP (1) EP1543008B1 (es)
JP (1) JP4799864B2 (es)
KR (1) KR20050057520A (es)
CN (1) CN1694886A (es)
AR (1) AR041347A1 (es)
AT (1) ATE377600T1 (es)
AU (1) AU2003272476B2 (es)
CA (1) CA2499756C (es)
DE (1) DE60317353T2 (es)
ES (1) ES2293015T3 (es)
MX (1) MXPA05003120A (es)
MY (1) MY134589A (es)
NZ (2) NZ538685A (es)
PE (1) PE20050081A1 (es)
TW (1) TW200413378A (es)
WO (1) WO2004026877A1 (es)
ZA (1) ZA200502375B (es)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU756699B2 (en) * 1996-12-03 2003-01-23 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
CN100537571C (zh) 2002-04-19 2009-09-09 细胞基因组公司 咪唑并[1,2-а]吡嗪-8-基胺,其制备方法及使用方法
EP1767535B1 (en) 2002-08-23 2009-12-02 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
WO2004022562A1 (en) 2002-09-09 2004-03-18 Cellular Genomics, Inc. 6-ARYL-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF
US7576085B2 (en) * 2002-09-23 2009-08-18 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
JP2006503838A (ja) * 2002-09-23 2006-02-02 シェーリング　コーポレイション サイクリン依存性キナーゼインヒビターとしての新規イミダゾピラジン
NZ538685A (en) * 2002-09-23 2008-02-29 Schering Corp Imidazopyrazines as cyclin dependent kinase inhibitors
WO2004072080A1 (en) 2003-02-10 2004-08-26 Cellular Genomics, Inc. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of hsp90 complex activity
US7157460B2 (en) * 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7186832B2 (en) * 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US20060183746A1 (en) * 2003-06-04 2006-08-17 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
WO2005005429A1 (en) * 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
US7259164B2 (en) * 2003-08-11 2007-08-21 Cgi Pharmaceuticals, Inc. Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity
WO2005061519A1 (en) 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
WO2006023931A2 (en) 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
CA2576159A1 (en) * 2004-08-27 2006-03-02 Cyclacel Limited Purine and pyrimidine cdk inhibitors and their use for the treatment of autoimmune diseases
EP1812439B2 (en) * 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
RU2402544C2 (ru) * 2005-01-14 2010-10-27 Си Джи Ай ФАРМАСЬЮТИКАЛЗ, ИНК. 1,3-диарилзамещенные мочевины как модуляторы киназной активности
WO2007024294A2 (en) * 2005-05-03 2007-03-01 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
EP1928237A4 (en) * 2005-09-02 2011-03-09 Abbott Lab NEW HETEROCYCLES BASED ON IMIDAZO
CN101300233A (zh) * 2005-09-09 2008-11-05 先灵公司 氮杂稠合的细胞周期蛋白依赖性激酶抑制剂
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
CA2628534A1 (en) * 2005-11-10 2007-05-18 Schering Corporation Methods for inhibiting protein kinases
KR20080074963A (ko) * 2005-11-10 2008-08-13 쉐링 코포레이션 단백질 키나제 억제제로서의 이미다조피라진
CA2653506A1 (en) * 2006-05-31 2007-12-06 Galapagos Nv. Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases
CA2654202A1 (en) * 2006-06-06 2007-12-21 Schering Corporation Imidazopyrazines as protein kinase inhibitors
US20090175852A1 (en) 2006-06-06 2009-07-09 Schering Corporation Imidazopyrazines as protein kinase inhibitors
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
SG175609A1 (en) 2006-10-09 2011-11-28 Takeda Pharmaceutical Kinase inhibitors
PE20080931A1 (es) * 2006-11-08 2008-07-19 Schering Corp Imidazopirazinas como inhibidores de proteina quinasa
JP2010510222A (ja) * 2006-11-17 2010-04-02 シェーリング コーポレイション 増殖性障害に対する併用療法
WO2008065198A1 (en) * 2006-12-01 2008-06-05 Galapagos N.V. Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases
CN101652069A (zh) * 2007-03-27 2010-02-17 艾博特公司 新的基于咪唑并的杂环化合物
WO2008138843A1 (en) * 2007-05-10 2008-11-20 Galapagos N.V. Imidazopyridines and triazolopyrimidines useful for the treatment of joint degenerative & inflammatory diseases
US8148369B2 (en) * 2007-05-10 2012-04-03 Janssen Pharmaceutica Nv Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
CA2690557A1 (en) * 2007-06-14 2008-12-24 Schering Corporation Imidazopyrazines as protein kinase inhibitors
DE102007032349A1 (de) * 2007-07-11 2009-01-15 Bayer Healthcare Ag Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
WO2009017701A2 (en) * 2007-07-31 2009-02-05 Schering Corporation Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment
GB0716292D0 (en) * 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
PE20091074A1 (es) * 2007-12-13 2009-07-26 Bayer Healthcare Ag Triazolotriazinas y triazolopirazinas y su uso
US20090221612A1 (en) 2008-02-13 2009-09-03 Mitchell Scott A Certain substituted amides, method of making, and method of use thereof
DE102008023801A1 (de) 2008-05-15 2009-11-19 Bayer Schering Pharma Aktiengesellschaft Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine
WO2010068258A1 (en) 2008-12-08 2010-06-17 Cgi Pharmaceuticals, Inc. Imidazopyrazine syk inhibitors
VN28228A1 (en) 2008-12-08 2011-12-26 Gilead Connecticut Inc Imidazopyrazine Syk inhibitors
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
KR101792837B1 (ko) * 2009-04-16 2017-11-02 푼다시온 센트로 나시오날 드 인베스티가시오네스 온콜로기카스 카를로스Ⅲ 키나아제 억제제로서 사용을 위한 이미다조피라진
US8993535B2 (en) 2009-09-04 2015-03-31 Merck Sharp & Dohme Corp. Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
JP5641664B2 (ja) 2009-10-30 2014-12-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ イミダゾ［１，２−ｂ］ピリダジン誘導体およびＰＤＥ１０阻害剤としてのそれらの使用
WO2011092120A1 (en) * 2010-01-29 2011-08-04 Nerviano Medical Sciences S.R.L. 6,7- dihydroimidazo [1,5-a] pyrazin-8 (5h) - one derivatives as protein kinase modulators
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
BR112012022943A2 (pt) 2010-03-11 2018-06-05 Gilead Connecticut Inc inibidores de syk de imidazopiridnas
US9468642B2 (en) 2010-03-18 2016-10-18 Bayer Intellectual Property Gmbh Imidazopyrazines
ES2555261T3 (es) 2010-06-01 2015-12-30 Bayer Intellectual Property Gmbh Imidazopirazinas sustituidas
MX339640B (es) 2010-06-09 2016-06-01 Janssen Pharmaceutica Nv * Derivados de 5, 6-dihidro-2h-[1, 4] oxazin-3-il-amina utiles como inhibidores de la beta-secretasa (bace).
JP2013545779A (ja) * 2010-12-17 2013-12-26 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン
JP5824065B2 (ja) * 2010-12-17 2015-11-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン
EP2651950A1 (en) 2010-12-17 2013-10-23 Bayer Intellectual Property GmbH 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
CN103403006B (zh) 2010-12-17 2015-11-25 拜耳知识产权有限责任公司 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的6-硫代-取代的咪唑并吡嗪
NZ610948A (en) * 2010-12-22 2014-06-27 Janssen Pharmaceutica Nv 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (bace)
SG192963A1 (en) 2011-03-01 2013-09-30 Janssen Pharmaceutica Nv 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (bace)
US9845326B2 (en) 2011-03-09 2017-12-19 Janssen Pharmaceutica Nv Substituted 3,4-dihydropyrrolo[1,2-A]pyrazines as beta-secretase (BACE) inhibitors
WO2013000924A1 (en) 2011-06-27 2013-01-03 Janssen Pharmaceutica Nv 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES
EP2863909B1 (en) 2012-06-26 2020-11-04 Janssen Pharmaceutica N.V. Combinations comprising 4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline compounds as pde 2 inhibitors and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
EP2869822B1 (en) 2012-07-09 2016-09-14 Janssen Pharmaceutica, N.V. Inhibitors of phosphodiesterase 10 enzyme
KR102243134B1 (ko) 2013-06-12 2021-04-22 얀센 파마슈티카 엔.브이. 베타-세크레타제(bace) 저해제로서의 4-아미노-6-페닐-5,6-디하이드로이미다조[1,5-a]피라진 유도체
WO2014198851A1 (en) 2013-06-12 2014-12-18 Janssen Pharmaceutica Nv 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazin-3(2h)-one derivatives as inhibitors of beta-secretase (bace)
US9751886B2 (en) 2013-06-12 2017-09-05 Janssen Pharmaceutica Nv 4-amino-6-phenyl-6,7-dihydro[1,2,3]triazolo[1,5-A]pyrazine derivatives as inhibitors of beta-secretase (BACE)
KR20170116203A (ko) 2013-07-30 2017-10-18 질레드 코네티컷 인코포레이티드 Ｓｙｋ 억제제의 제제
AP2016009008A0 (en) 2013-07-30 2016-01-31 Gilead Connecticut Inc Polymorph of syk inhibitors
US9687492B2 (en) 2013-12-04 2017-06-27 Gilead Sciences, Inc. Methods for treating cancers
TWI662037B (zh) 2013-12-23 2019-06-11 美商基利科學股份有限公司 脾酪胺酸激酶抑制劑
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
KR101864589B1 (ko) * 2014-05-28 2018-07-04 상하이 포천 파마슈티컬 씨오 엘티디 특정한 단백질 키나아제 억제제
EA201790086A1 (ru) 2014-07-14 2017-07-31 Джилид Сайэнс, Инк. Комбинации для лечения раковых заболеваний
ES2768823T3 (es) 2014-12-18 2020-06-23 Janssen Pharmaceutica Nv Derivados de 2,3,4,5-tetrahidropiridin-6-amina y 3,4-dihidro-2H-pirrol-5-amina útiles como inhibidores de beta-secretasa
MX2018006250A (es) 2015-11-18 2018-09-05 Genzyme Corp Biomarcador de enfermedad poliquistica renal y usos del mismo.
WO2019040298A1 (en) 2017-08-25 2019-02-28 Gilead Sciences, Inc. SYK INHIBITORY POLYMORPHS
US11339168B2 (en) 2019-02-22 2022-05-24 Kronos Bio, Inc. Crystalline forms of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as Syk inhibitors
WO2021249417A1 (zh) * 2020-06-09 2021-12-16 赛诺哈勃药业（成都）有限公司 杂环化合物及其衍生物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2607813B1 (fr) * 1986-12-05 1989-03-31 Montpellier I Universite Alkylamino-8 imidazo (1,2-a) pyrazines et derives, leur preparation et leur application en therapeutique
US5137876A (en) * 1990-10-12 1992-08-11 Merck & Co., Inc. Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same
PT778277E (pt) 1995-12-08 2003-11-28 Pfizer Derivados heterociclicos substituidos como antagonistas do crf
JPH1166560A (ja) * 1997-08-15 1999-03-09 Sony Corp 光情報記録方法及び光情報記録装置
WO2002006286A2 (en) 2000-07-14 2002-01-24 Bristol-Myers Squibb Pharma Company IMIDAZO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
WO2002010162A1 (en) 2000-07-26 2002-02-07 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases
AU2002225096B8 (en) * 2000-12-20 2006-07-27 Ipsen Pharma S.A.S. Cyclin-dependent kinase (CDK) and glycogen synthase kinase-3 (GSK-3) inhibitors
CA2436487A1 (en) * 2001-01-30 2002-08-08 Cytopia Pty Ltd. Methods of inhibiting kinases
CN100537571C (zh) 2002-04-19 2009-09-09 细胞基因组公司 咪唑并[1,2-а]吡嗪-8-基胺,其制备方法及使用方法
NZ538685A (en) * 2002-09-23 2008-02-29 Schering Corp Imidazopyrazines as cyclin dependent kinase inhibitors
JP2006503838A (ja) * 2002-09-23 2006-02-02 シェーリング　コーポレイション サイクリン依存性キナーゼインヒビターとしての新規イミダゾピラジン

Also Published As

Publication number Publication date
AU2003272476A1 (en) 2004-04-08
NZ538685A (en) 2008-02-29
MXPA05003120A (es) 2005-06-22
JP4799864B2 (ja) 2011-10-26
CA2499756C (en) 2011-07-12
ATE377600T1 (de) 2007-11-15
KR20050057520A (ko) 2005-06-16
CN1694886A (zh) 2005-11-09
ES2293015T3 (es) 2008-03-16
CA2499756A1 (en) 2004-04-01
ZA200502375B (en) 2005-09-27
AU2003272476B2 (en) 2007-07-05
US7432265B2 (en) 2008-10-07
TW200413378A (en) 2004-08-01
US6919341B2 (en) 2005-07-19
AR041347A1 (es) 2005-05-11
EP1543008A1 (en) 2005-06-22
US20050130980A1 (en) 2005-06-16
HK1072056A1 (en) 2005-08-12
WO2004026877A1 (en) 2004-04-01
JP2006507253A (ja) 2006-03-02
NZ563374A (en) 2009-06-26
DE60317353D1 (de) 2007-12-20
DE60317353T2 (de) 2008-08-28
US20040063715A1 (en) 2004-04-01
MY134589A (en) 2007-12-31
EP1543008B1 (en) 2007-11-07

Similar Documents

Publication Publication Date Title
PE20050081A1 (es) Nuevas imidazopirazinas como inhibidores de cinasas dependientes de ciclinas
ATE433447T1 (de) Pyrimiidinverbindungen
UY29458A1 (es) Heterociclos sustituidos y usos de los mismos
ECSP055640A (es) Composiciones de pirazol útiles como inhibidores de gsk-3
BRPI0513405A (pt) tienopirimidinas úteis como inibidores de aurora quinase
BRPI0607455A2 (pt) composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
EA200700188A1 (ru) Производные замещенного 2-алкилхиназолинона как ингибиторы parp
BRPI0408817A (pt) composto, processo de preparação do mesmo, composição farmacêutico, e, utilização de um composto
SV2005001973A (es) Quinolinas utiles en el tratamiento de enfermedades cardiovasculares ref. wyth0090-504 (am101500)
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
PE20090902A1 (es) Combinacion de un antimitotico e inhibidor de aurora quinasa como agentes anticancerigenos
PE20070621A1 (es) 2-amino-7,8-dihidro-6h-pirido(4,3-d)pirimidina-5-onas
ECSP066717A (es) Compuestos de quinolina sustituidos
UY29803A1 (es) Derivados de adeninas, composiciones farmacéuticas conteniéndolos, procedimientos de preparación y aplicaciones
ATE365740T1 (de) Substituierte pyrazolopyrimidine
EA200601002A1 (ru) 6-алкенил и 6-фенилалкил замещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза) полимеразы
UY28516A1 (es) Derivados de quinazolina
BR0318503A (pt) quinolinas substituìdas como inibidores de enzima proteìna tirosina cinase
BRPI0412659A (pt) isÈmero c de cci-779, seu processo de preparação, composição farmacêutica compreendendo o mesmo e pacote farmacêutico contendo o referido composto
GT200400133AA (es) Derivados de pirrolo[3,4-c] pirazol, activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden. (solicitud fraccionaria no. 1, derivada de la patente no. pi-2004-0133).
BR0208741A (pt) Derivados de piperidina
CR9663A (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
BRPI0413565B8 (pt) análogos de quinazolina como inibidores de receptor de erbb2, seu uso e sua composição farmacêutica
CY1109808T1 (el) Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α
DE602004011204D1 (de) Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.

Legal Events

Date Code Title Description
FC Refusal